CannaQ › Blog
The CannaQ blog
Evidence summaries on cannabinoid research. Every article is built from sources we can name, shows how certain the evidence is, and is checked by a person before it goes live.
Articles
Filter by topic. Topics follow the list of areas we track.
- Epilepsy
Cannabidiol in Dravet and Lennox–Gastaut syndromes: what the phase 3 trials found
Three placebo-controlled trials tested a pharmaceutical cannabidiol (CBD) oral solution in two rare, severe childhood-onset epilepsies. Here is what they measured, what they found and what they leave open.
- Chronic pain
Cannabis-based medicines and chronic pain: what the systematic reviews say
Two large reviews of randomised trials, including a Cochrane review updated in January 2026, find small or uncertain benefits alongside more frequent side effects.
- Multiple sclerosis
Cannabinoids and multiple sclerosis: spasticity, pain and side effects
A 2022 Cochrane review of 25 randomised trials found moderate-certainty evidence for a short-term effect on spasticity with one THC/CBD spray, and much weaker evidence for other symptoms.
- In preparation
Pioneers of cannabinoid science: Raphael Mechoulam
A sourced timeline of the discoveries that shaped the field, and what they do and don’t tell us about treatment.
- Planned
How to read a clinical trial
What sample size, control groups and blinding tell you, and what a headline leaves out.
- Planned
THC and CBD are not the same thing
Two cannabinoids with different effects and different risks.
A topic on this list does not mean a proven cannabis treatment exists. See how we grade evidence.
CannaQ